Cardiac imaging
"Magnetic resonance imaging" (originally called nuclear magnetic resonance imaging), an imaging methodology based on aligning the spin axis of nuclei within molecules of the object being visualized using both powerful superconducting magnets and radio frequency and detectors. Cardiology uses are growing, especially since MRI differentiates soft tissues better than CT and allows for comprehensive exams including the quantitative assessment of size, morphology, function, and tissue characteristics in one single session. Current implementations for Cardiology uses are sometimes limited by lengthy protocols, claustrophobia and contraindications based on some complex metallic implants (pacemakers, defibrillators, insulin pumps), while artificial valves and coronary stents are generally not problematic. Image quality can be reduced by the continuous movement of heart structures. There is a promising future in cardiac MRI by more efficient scans, increasing availability of scanners and more widespread knowledge about its clinical application.
Prostate biopsy
Since the mid-1980s, TRUS biopsy has been used to diagnose prostate cancer in essentially a blind fashion because prostate cancer cannot be seen on ultrasound due to poor soft tissue resolution. However, multi-parametric magnetic resonance imaging (mpMRI) has since about 2005 been used to better identify and characterize prostate cancer. A study correlating MRI and surgical pathology specimens demonstrated a sensitivity of 59% and specificity of 84% in identifying cancer when T2-weighted, dynamic contrast enhanced, and diffusion-weighted imaging were used together. Many prostate cancers missed by conventional biopsy are detectable by MRI-guided targeted biopsy. In fact, a side-by-side comparison of TRUS versus MRI-guided targeted biopsy that was conducted as a prospective, investigator-blinded study demonstrated that MRI-guided biopsy improved detection of significant prostate cancer by 17.7%, and decreased the diagnosis of insignificant or low-risk disease by 89.4%.